

#4 8-25-01
RECEIVED
AUG 21 2001
TECHNICAL CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mary Capelli-Schellpfeffer

Application No.: 09/810,939 Group Art Unit: 1615

Filed: March 16, 2001 Examiner: Unknown

Title: METHODS FOR IMPROVING SIZE AND APPEARANCE OF A WOUND

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>8-15-01</u>	<u>Linda M Crawford</u>
Date	Signature
<u>Linda M Crawford</u>	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
 - ☒ Copies of the cited references are enclosed. (AA-AK; AA2-AI2; AL-AO; AR-AZ; AR2-AZ2; AR3-AZ3; AR4-AZ4; AR5-AT5)
 - ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
 - ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
 - ☒ The "concise explanation" requirement (non-English references) for references AO, AS3, AT3 and AZ4 under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☒ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

☐ A copy of each above-cited application, including the current claims, is enclosed.

☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.

☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By


Jacqueline M. Arendt

Registration No.: 43,474

Telephone: (781) 861-6240

Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated:

8-15-01

PTO-149 REPRODUCED

ATTORNEY DOCKET NO.
3066.1000-001

APPLICATION NO.
09/810,939

APPLICANT
Mary Capelli-Schellpfeffer

FILING DATE
March 16, 2001

GROUP
1615

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

August 15, 2001

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS


EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	2,113,374	Apr 5, 1938	Hall	260	111	
	AB	3,419,006	Dec 31, 1968	King	128	268	
	AC	3,664,343	May 23, 1972	Assarsson	128	284	
	AD	3,800,792	Apr 2, 1974	McKnight et al.	128	156	
	AE	3,993,551	Nov 23, 1976	Assarsson et al.	204	159.14	
	AF	4,126,681	Nov 21, 1978	Reller	424	234	
	AG	4,552,138	Nov 12, 1985	Hofeditz et al.	128	156	
	AH	4,646,730	Mar 3, 1987	Schonfeld, et al.	728	156	
	AI	4,659,700	Apr 21, 1987	Jackson	514	55	
	AJ	4,838,253	Jun 13, 1989	Brassington et al.	128	156	
	AK	4,909,244	Mar 20, 1990	Quarfoot et al.	128	156	
	AA2	4,991,574	Feb 12, 1991	Pocknell	128	156	
	AB2	5,013,769	May 7, 1991	Murray et al.	523	111	
	AC2	5,132,119	Jul 21, 1992	Lee	424	646	
	AD2	5,552,162	Sep 3, 1996	Lee	424	646	
	AE2	5,569,678	Oct 29, 1996	Lee	514	654	
	AF2	5,700,688	Dec 23, 1997	Lee et al.	435	287.1	
	AG2	5,756,350	May 26, 1998	Lee et al.	435	325	
	AH2	5,902,609	May 11, 1999	Lee	424	646	
	AI2	3,119,739	Jan 28, 1964	Campbell	167	58	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AL	1,292,503	11 Oct 1972	United Kingdom				
	AM	842,404	27 July 1960	United Kingdom				
	AN	938,555	18 Dec 1973	Canada				
	AO	JP48003364	30 Jan 1973	Japan (English Abstract)				X

EXAMINER

DATE CONSIDERED



AUG 21 2001
TECH CENTER 1600/2900

RECEIVED

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE
IN AN APPLICATION

August 15, 2001

(Use several sheets if necessary)


ATTORNEY DOCKET NO.
3066.1000-001APPLICATION NO.
09/810,939APPLICANT
Mary Capelli-SchellpfefferFILING DATE
March 16, 2001GROUP
1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Linaires, H.A. and Larson, D.L., "Proteoglycans and Collagenase in Hypertrophic Scar Formation," <i>Plast. & Reconstr. Surg.</i> , 62(4):589-593 (1978, October).
AS	Linaires, H.A., "Measurement of Collagen-Proteoglycan Interaction in Hypertrophic Scars," <i>Plast. & Reconstr. Surg.</i> , 71(6):818-820 (1983, June).
AT	Welgus, H.G., et al. "Human Skin Fibroblast Collagenase," <i>J. Biolog. Chem.</i> , 256(18):9516-9521 (1981, September).
AU	Reiffel, R.S., "Prevention of Hypertrophic Scars by Longterm Paper Tape Application," <i>Plast. & Reconstr. Surg.</i> , 96:1715-1718 (1995, December).
AV	Quinn, K.J., et al., "Non-Pressure treatment of hypertrophic scars," <i>Burns</i> , 12:102-108 (1985).
AW	Quinn, K.J. "Silicone gel in scar treatment," <i>Burns</i> , 13:S33-S40 (1987).
AX	Fulton, J.E., "Silicone Gel Sheeting for the Prevention and Management of Evolving Hypertrophic and Keloid Scars," <i>Dermatol. Surg.</i> , 21:947-951 (1995).
AY	Gold, M.H., "A controlled clinical trial of topical silicone gel sheeting in the treatment of hypertrophic scars and keloids," <i>J. of Amer. Aca. of Dermatol.</i> , 30(3):506-507 (1994, March).
AZ	Jeffrey, J.J., et al., "Studies on the Activation Energy and Deuterium Isotope Effect of Human Skin Collagenase on Homologous Collagen Substrates," <i>J. of Bio. Chem.</i> , 258(18):11123-11127 (1983).
AR2	Katz, B.E., "Silicone Gel Sheeting in Scar Therapy," <i>Cutis</i> , 56(1):65-67 (1995, July).
AS2	Stolar, M.E., et al., "The Effect of Various Ointment Bases on the Percutaneous Absorption of Salicylates I," <i>J. of Amer. Pharm. Assn.</i> , 49(3):144-147 (1960, March).
AT2	Welgus, H.G., et al., "The Collagen Substrate Specificity of Human Skin Fibroblast Collagenase," <i>J. of Bio. Chem.</i> , 256(18):9511-9515 (1981, September).
AU2	Wong, T.-W., et al., "Silicone Cream Occlusive Dressing-A Novel Noninvasive Regimen in the Treatment of Keloid." <i>Dermatol.</i> , 192(4):329-333 (1996).
AV2	Sawada, Y. and Sone, K., "Hydration and occlusion treatment for hypertrophic scars and keloids," <i>Brit. J. of Plastic. Surg.</i> , 45(8):599-603 (1992).

EXAMINER


DATE CONSIDERED



TECH CENTER 1600/2900

AUG 21 2001

RECEIVED



TECH CENTER 1600/2800

AUG 21 2001

RECEIVED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3066.1000-001	APPLICATION NO. 09/810,939
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Mary Capelli-Schellpfeffer	
August 15, 2001		FILING DATE March 16, 2001	GROUP 1615
(Use several sheets if necessary)			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AW2	Mercer, N.S.G., "Silicone gel in the treatment of keloid scars," <i>Brit. J. of Plast. Surg.</i> , 42(1):83-87 (1989, January).		
AX2	Ahn, S.T., et al., "Topical silicone gel: A new treatment for hypertrophic scars," <i>Surg.</i> , 106(4):781-787 (1989, October).		
AY2	Phillips, T.J., et al., "A Randomized Controlled Trial of Hydrocolloid Dressing in the Treatment of Hypertrophic Scars and Keloids," <i>Dermatol. Surg.</i> , 22:775-778 (1996).		
AZ2	Krieger, L.M., et al., "Thermal Response of the Epidermis to Surface Gels," <i>Surg. Forum</i> , 44:738-741 (1993).		
AR3	Shetlar, M.R., et al., "The hypertrophic scar: location of glycosaminoglycans within scars," <i>Burns</i> 4(1):14-19 (1977).		
AS3	Cinc, M., et al., "Polyethylene glycols as bases for preparing salicylic acid ointments," <i>Farm. Glas.</i> , 27(10):371-376 (1971). English abstract.		
AT3	Luedde, K.H., "Controlling the desorption of salicylic acid from salve bases and its absorption through the skin," <i>Acta Fac. Med. Univ. Brun.</i> , 40(1):183-187 (1972). English abstract.		
AU3	Gstirner, F. "Absorption of salicylic acid from modern ointment bases," <i>Chem. Abstr.</i> , 62:6347 (1965).		
AV3	Whitworth, Clyde W., "Effect of various liquids on the diffusion of salicylic acid from ointment bases," <i>J. Pharm. Sci.</i> , 57(9):1540-1543 (1968). Abstract.		
AW3	Kopp, E. and Ghosh, S., "Inhibition of NF-kB by Sodium Salicylate and Aspirin," <i>Science</i> , 265: 956-58, (August 1994).		
AX3	Pomerantz, J. and Baltimore, D., "A Cellular Rescue Team", <i>Nature</i> , 406: 26-27,29, (July 2000).		
AY3	Pen, E., "Building a Better Aspirin", <i>Science</i> , 280: 1191-1192, (May, 1998).		
AZ3	Roberts, S., "Take two: Aspirin", <i>Am. Chem. Society, Modern Drug Discovery</i> , pp. 23-24,27, (Oct. 2000).		
AR4	Ehrlich, H.P., "The Physiology of Wound Healing", <i>Advances in Wound Care</i> , 11:7, pp 326-28 (Nov./Dec. 1998)		

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

August 15, 2001

(Use several sheets if necessary)


ATTORNEY DOCKET NO.
3066.1000-001APPLICATION NO.
09/810,939APPLICANT
Mary Capelli-SchellpfefferFILING DATE
March 16, 2001GROUP
1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AS4	Mentor, A. et al., "Wounds and Scars: Therapeutic Options", Supplement to Drug Topics, (March, 1998)
AT4	"Scar Prevention-Scar Improvement", Consensus Conference Report, First Intl. Scar Consensus Conference, Klaschka, F., Chairman, Vienna, (Nov. 27-28, 1996).
AU4	Barnes, Peter J., "Therapeutic Strategies for Allergic Diseases", Nature, 402 supp: B31-38, (25 Nov. 1999).
AV4	Fisher, G.J., et al., "Molecular Basis of Sun-Induced Premature Skin Ageing and Retinoid Antagonism," Nature, 379: 335-9, (Jan. 1996).
AW4	Buttar, N.S., and Wang, K.K., "The "Aspirin" of the New Millennium: Cyclooxygenase-2 Inhibitors", Mayo Clinic Proceedings, 75(10): 1027-1038 (Oct. 2000).
AX4	Abraham, D.J., et al. "Tumor Necrosis Factor Alpha Suppresses the Induction of Connective Tissue Growth Factor by Transforming Growth Factor-Beta in Normal and Scleroderma Fibroblasts," J. Biol Chem, 275:(20) 15220-5, (May 2000).
AY4	Klahr, S. and Morrissey, J.J., "Comparative Study of ACE Inhibitors and Angiotensin II Receptor Antagonists in Interstitial Scarring," Kidney Int., 52; Suppl. 63: S111-1114, (Dec. 1997).
AZ4	Wang, J., "The Effect of Cyclooxygenase-2 Inhibitor on Acute Lung Injury", Zhonghua Jiehe He Huxi Zazhi, 22:(6) (English Abstract) 351-53, (June 1999).
AR5	Kaplan-Machlis, B. and Klostermeyer, B.S., "The Cyclooxygenase-2 Inhibitors: Safety and Effectiveness," Annals of Pharmacotherapy 33(9): 979-988, (Sept. 1999).
AS5	Simon, Lee S., "Role and Regulation of Cyclooxygenase-2 During Inflammation," American Journal of Medicine, 106 (5,B):37S-42S, (May 31, 1999).
AT5	Brooks, P., et al, "Interpreting the Clinical Significance of the Differential Inhibition of Cyclooxygenase-1 and Cyclooxygenase-2," Rheumatology (Oxford), 38(8): 779-88, (Aug., 1999).

EXAMINER

DATE CONSIDERED



TECH CENTER 1600/2900

AUG 21 2001

RECEIVED